This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vivus Weight-Loss Drug Launch In Early Trouble (Updated)

Updated with new information.

MOUNTAIN VIEW, Calif. ( TheStreet) -- Vivus (VVUS - Get Report)provided investors with the first detailed looked at the commercial launch of the weight-loss pill Qsymia on Tuesday. The picture painted wasn't pretty.

Qsymia sales in the third quarter totaled $41,000 well below the analyst consensus estimate of $310,000. Vivus gets a pass on the September quarter, however, because Qsymia was only available for 10 days.

In the six weeks of the Qsymia launch to date, 3,504 patients are currently on Qsymia, Vivus reported. The average monthly price for a 30-day supply of Qsymia is $160, the company added.

Do the math: If all 3,504 patients remain on Qsymia, sales in the fourth quarter would total $1.7 million. More patients will start Qsymia as the fourth quarter progresses and add to total revenue, of course, but at this point, it seems almost impossible for Vivus to meet analysts' consensus estimate of approximately $24.3 million for the December quarter, according to Bloomberg.

Some analysts have already started cutting their Qsymia forecasts, others will most certainly do so now. Minutes after Vivus' call ended, Lazard Capital cuts its 2013 Qsyma sales projection to $80 million from $204 million. Investors had already clued into the poor Qsymia launch, with Vivus shares falling 30% since in mid-October.

Vivus shares fell another 21% to $11.83 in Tuesday trading.

On its conference call, Vivus said 30% of patients who are prescribed Qsymia by a doctor are choosing not to pick up their prescriptions due to the out-of-pocket cost. This high rate of prescription abandonment is a concern the company is taking very seriously, said Vivus chief commercial officer Mike Miller.

At present, about 20% of patients are receiving insurance reimbursement coverage for Qsymia with an average co-pay of $60 per month. Vivus expects insurance coverage to grow to about 30% one year into the drug's launch.

Vivus executives stressed that Qsymia was still in the early stages of its commercial launch and that selling a new weight-loss pill was a challenge. "We look at it as the launch of a brand new category with very little support and education going on," said Miller.

With regards to Stendra, Vivus's erectile dysfunction pill, Vivus said it was making "good progress" on talks with potential partners to launch the drug in the U.S., Europe and the rest of the world. However, the FDA approved Stendra in late April.

Vivus lost $40.4 million, or 40 cents per share, in the third quarter.

Weight-loss pill competitor Arena Pharmaceuticals (ARNA - Get Report) reports third-quarter results after Tuesday's market close. Arena is expected to launch its pill, Belviq, early next year.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.58 -0.32%
VVUS $1.37 0.00%
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs